Wearable pacemaker

A Halloween blackout in Minneapolis exposed a brutal design flaw: a machine meant to keep a heart beating still depended on the wall socket. When power failed in 1957, pediatric cardiac patients attached to bulky external pacemakers were suddenly at risk. Out of that failure came the wearable pacemaker, a device that moved cardiac pacing off the cart, onto the body, and toward the implantable future.

The adjacent possible began in Toronto, not Minnesota. John Hopps and his colleagues had already built the external pacemaker in 1950, proving that timed electrical pulses could restart or sustain a heart. But those systems were large vacuum-tube machines, useful in hospitals and miserable everywhere else. At the same time, the bipolar-junction transistor had begun shrinking electronics and cutting power demands. Open-heart surgery then created a new clinical niche: children and adults who survived complex procedures but developed temporary heart block afterward. Surgeons could save the anatomy and still lose the patient to rhythm failure.

C. Walton Lillehei at the University of Minnesota was living inside that gap. After the Twin Cities blackout around Halloween 1957, he asked Earl Bakken of Medtronic for a battery-powered pacemaker that would not die when the building did. Bakken did not start from a clean sheet. He adapted a transistorized metronome circuit published in Popular Electronics, reworked it for pacing, and built a prototype in about four weeks. The result was small enough to be worn, battery-powered rather than plug-bound, and simple enough to reach patients almost immediately.

That is niche construction in medical form. Heart surgery had created a population of patients who needed reliable temporary pacing. The bipolar-junction transistor gave engineers a way to meet that need without heat-heavy vacuum tubes and wall current. Once those two conditions overlapped, the wearable pacemaker became far more than a convenience upgrade. It changed what doctors expected pacing technology to do. A pacemaker no longer had to be furniture.

Medtronic turned that shift into a product and a distribution system. The company commercialized the device as the Medtronic 5800 and shipped it well beyond the University of Minnesota. What had been a local rescue tool became a repeatable clinical platform. That commercialization matters because many inventions die in the gap between prototype and routine care. Medtronic closed that gap, and in doing so helped define the medical-device model of rapid engineer-clinician iteration around a hospital problem.

Path dependence shows up in what happened next. Once physicians had seen that transistorized, battery-powered pacing could be safe at the bedside and on the body, the next question was obvious: why stop outside the skin? The wearable pacemaker did not itself solve long-term lead reliability, hermetic sealing, or implantable batteries, but it made the implantable pacemaker easier to imagine, test, and justify. In Sweden, surgeons and engineers pushed that next step almost immediately, translating portable pacing into the first implanted systems. The wearable device had already shifted the clinical and engineering baseline.

The invention also reveals how medical technology often advances by changing constraints rather than changing the underlying therapy. The therapy here remained the same as in the external pacemaker: rhythmic electrical stimulation of the heart. What changed was portability, power source, and trust. Patients were no longer tethered to a cart. Hospitals were less exposed to outages. Surgeons gained a bridge through the dangerous post-operative period.

Wearable pacing rarely gets the same glory as the implantable pacemaker, but it was the hinge. It translated the proof of concept from the external pacemaker into a human-scale device, and it used the bipolar-junction transistor to turn life support into something mobile. In that sense it behaved like a keystone species inside cardiac-device history: small on its own, but decisive in stabilizing the path from temporary pacing to implantable therapy. That combination of miniaturization, reliability, and clinical urgency made the next step feel less like science fiction and more like engineering.